Treatment Trials

1 Clinical Trials for Various Conditions

TERMINATED

Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors

Description

The objective of this study is to determine the safety, pharmacokinetics, maximum tolerated dose/recommended Phase 2 dose, and efficacy of PLX7486.

Conditions

Solid Tumor Tumors of Any Histology With Activating Trk (NTRK) Point or NTRK Fusion Mutations Tenosynovial Giant Cell Tumor